Quantifying Child Mortality Reductions Related to Measles Vaccination

DSpace/Manakin Repository

Quantifying Child Mortality Reductions Related to Measles Vaccination

Citable link to this page

 

 
Title: Quantifying Child Mortality Reductions Related to Measles Vaccination
Author: Goldhaber-Fiebert, Jeremy D.; Lipsitch, Marc; Mahal, Ajay; Zaslavsky, Alan M.; Salomon, Joshua A.

Note: Order does not necessarily reflect citation order of authors.

Citation: Goldhaber-Fiebert, Jeremy D., Marc Lipsitch, Ajay Mahal, Alan M. Zaslavsky, and Joshua A. Salomon. 2010. Quantifying child mortality reductions related to measles vaccination. PLoS ONE 5(11): e13842.
Full Text & Related Files:
Abstract: Background: This study characterizes the historical relationship between coverage of measles containing vaccines (MCV) and mortality in children under 5 years, with a view toward ongoing global efforts to reduce child mortality. Methodology/Principal Findings: Using country-level, longitudinal panel data, from 44 countries over the period 1960–2005, we analyzed the relationship between MCV coverage and measles mortality with (1) logistic regressions for no measles deaths in a country-year, and (2) linear regressions for the logarithm of the measles death rate. All regressions allowed a flexible, non-linear relationship between coverage and mortality. Covariates included birth rate, death rates from other causes, percent living in urban areas, population density, per-capita GDP, use of the two-dose MCV, year, and mortality coding system. Regressions used lagged covariates, country fixed effects, and robust standard errors clustered by country. The likelihood of no measles deaths increased nonlinearly with higher MCV coverage (ORs: 13.8 [1.6–122.7] for 80–89% to 40.7 [3.2–517.6] for ≥95%), compared to pre-vaccination risk levels. Measles death rates declined nonlinearly with higher MCV coverage, with benefits accruing more slowly above 90% coverage. Compared to no coverage, predicted average reductions in death rates were −79% at 70% coverage, −93% at 90%, and −95% at 95%. Conclusions/Significance: 40 years of experience with MCV vaccination suggests that extremely high levels of vaccination coverage are needed to produce sharp reductions in measles deaths. Achieving sustainable benefits likely requires a combination of extended vaccine programs and supplementary vaccine efforts.
Published Version: doi:10.1371/journal.pone.0013842
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2973966/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:8605287
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters